Tiziana Life Sciences Ltd
TLSA
Positions held
Your positionsTLSA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $143.80M | Enterprise value | $132.62M | Trailing P/E | — | Forward P/E | -6.26 |
| PEG | — | Price / book | — | Beta | 0.44 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -9.2% | ROA | -116.0% | Debt / equity | 8.77 |
| Current ratio | 0.76 | Free cash flow | -$5.48M | Analyst recommendation | strong_buy | Mean target | $7.99 |
| 52w high | $2.25 | 52w low | $0.76 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$18.4M | -$11.9M | -$17.7M | -$15.4M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | $0.0M |
| Operating income | -$21.1M | -$15.8M | -$18.0M | -$14.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
2026-09-30 · MARKETS LIVE: Wall Street closes mixed as cooling inflation lifts Nasdaq
2026-09-28 · Tiziana doses first three patients in ALS trial of nasal antibody foralumab
2026-09-28 · Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
2026-09-21 · Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial
2026-09-21 · Tiziana Life Sciences to Announce Topline Data From Phase 2a Na-SPMS Trial in October
2026-09-21 · Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
2026-09-17 · Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
2026-09-17 · Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
2026-09-03 · Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
2026-08-24 · Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
Price (daily)
Full chart · RSI · MACD · patterns